PDCD1 and cancer: Intra-tumoral, intranodal, ID and IVroutes of administration have been used dosing of mRNA encoding immunostimulants, with most evaluations are currently in Phase I/II to assess the tolerability as monotherapy or combination therapy with other moieties, including either PD-1/PD-L1 antibodies or cancer vaccines [655].